<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650390</url>
  </required_header>
  <id_info>
    <org_study_id>M02-532</org_study_id>
    <nct_id>NCT00650390</nct_id>
  </id_info>
  <brief_title>Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab</brief_title>
  <acronym>PROWD</acronym>
  <official_title>Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The study was to explore the efficacy of adalimumab in subjects previously treated with
      infliximab and failed infliximab treatment due to lack of efficacy or intolerance. To explore
      the safety of adalimumab in subjects previously treated with infliximab.
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>40 mg adalimumab every other week</description>
    <other_name>ABT-D2E7</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females &gt;= 18 years of age

          -  ACR criteria for RA diagnosis for at least 6 months

          -  Active RA defined as a DAS 28 &gt;3.2 at study entry

          -  Unsatisfactory response, loss of response or intolerance to prior infliximab treatment

          -  A negative pregnancy test for females of childbearing potential

        Exclusion Criteria:

          -  Patient who had previous treatment with cyclophosphamide and chlorambucil

          -  Treatment within the last 8 weeks with infliximab

          -  Prior treatment with more than one DMARD or DMARD combination following infliximab
             treatment

          -  Prior treatment with biologics (Investigational or Commercial) RA therapies other than
             infliximab

          -  History of cancer, other than successfully treated squamous cell or basal cell
             carcinoma or lymphoproliferative disease

          -  Prior treatment with total lymphoid irradiation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>March 28, 2008</last_update_submitted>
  <last_update_submitted_qc>March 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lawrence McNamee</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

